← Leaderboards
Kevin James McHugh
Rice University
$3,609,617
Attributed
$3,857,454
Total exposure
7
Grants
7
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.1M · FY2017–25$2M$1.5M$1M$500K$0
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$3,857,454 · 7
By mechanism
R35$2,127,250 · 1
R21$838,699 · 2
R25$330,450 · 1
K22$266,997 · 1
R03$175,818 · 1
F32$118,240 · 1
Top collaborators
- Brian Mahon1 shared
- Carolyn Aitken Nichol1 shared
- Jeff Stear1 shared
Most similar at Rice University
Same institution · by research overlap
- Brian Mahon$82,613
- Carolyn Aitken Nichol$874,466
- Jeff Stear$82,613
Others in their field
Other Emerging Leaders on “Kinetics”
- Leonard Freedman · Leidos Biomedical Research, Inc.$241,865,009
- Lynn Briscoe · Leidos Biomedical Research, Inc.$93,294,869
- Yunda Huang · Fred Hutchinson Cancer Center$54,278,170
- Leonard Freedmand · Leidos Biomedical Research, Inc.$52,916,621
- Susan Abushakra · Alzheon, Inc.$47,265,244
- Kathleen Maletic Neuzil · Emory University$26,552,931
Research focus
KineticsParticleControlled ReleaseEncapsulatedFormulationExhibitsDoseRegimenStructurePolymersPreventPharmaceutical PreparationsDrug Delivery SystemsInterestIn VivoAreaMortalitySurfaceCommunicable DiseasesGlycolatesSiteInjectableAntigensVaccination
Grant awards (22)
Next-Generation Parenteral Drug Delivery Systems for Controlling Pharmacokinetics$384,181
R35 · FY2025 · GM · contact PI
Leveraging Controlled Release to Create a Single-Injection Post-Exposure Prophylactic for Rabies$232,765
R21 · FY2025 · AI · contact PI
Improving Vaccination through Biomimicry: Recapitulating the Antigen Kinetics of Native Infections using a Modular Vaccine Delivery System$226,702
R21 · FY2025 · AI · contact PI
Next-Generation Parenteral Drug Delivery Systems for Controlling Pharmacokinetics$384,181
R35 · FY2024 · GM · contact PI
Rice-HCC ACCELERATE: Augmenting Community College Education to Leverage Experiential Research and Advance Training Equity$330,450
R25 · FY2024 · AI · contact PI
Leveraging Controlled Release to Create a Single-Injection Post-Exposure Prophylactic for Rabies$191,655
R21 · FY2024 · AI · contact PI
Improving Vaccination through Biomimicry: Recapitulating the Antigen Kinetics of Native Infections using a Modular Vaccine Delivery System$187,577
R21 · FY2024 · AI · contact PI
Next-Generation Parenteral Drug Delivery Systems for Controlling Pharmacokinetics$6,129
R35 · FY2024 · GM · contact PI
Next-Generation Parenteral Drug Delivery Systems for Controlling Pharmacokinetics$384,181
R35 · FY2023 · GM · contact PI
Next-Generation Parenteral Drug Delivery Systems for Controlling Pharmacokinetics$73,536
R35 · FY2023 · GM · contact PI
Solvent Evaporator Equipment Supplement to R35GM143101$59,274
R35 · FY2023 · GM · contact PI
Next-Generation Parenteral Drug Delivery Systems for Controlling Pharmacokinetics$384,181
R35 · FY2022 · GM · contact PI
Electrosprayed Core-Shell Microparticles as a Pulsatile Vaccine Delivery Platform$72,948
R03 · FY2022 · EB · contact PI
Research Supplement to Promote Diversity: Mei-Li Laracuente (1R35GM143101 Parent Award)$67,406
R35 · FY2022 · GM · contact PI
Research Supplement to Promote Diversity: Carlos Torres (R03EB031495 Parent Award)$14,961
R03 · FY2022 · EB · contact PI
Research Supplement to Promote Diversity: Belvi Bwela (R03EB031495 Parent Award)$14,961
R03 · FY2022 · EB · contact PI
Next-Generation Parenteral Drug Delivery Systems for Controlling Pharmacokinetics$384,181
R35 · FY2021 · GM · contact PI
Biomaterial Strategies for Modulating the Immune Response$106,749
K22 · FY2021 · AI · contact PI
Electrosprayed Core-Shell Microparticles as a Pulsatile Vaccine Delivery Platform$72,948
R03 · FY2021 · EB · contact PI
Biomaterial Strategies for Modulating the Immune Response$160,248
K22 · FY2020 · AI · contact PI
Fluorescence-based molecular imaging of in vivo release kinetics$61,174
F32 · FY2018 · EB · contact PI
Fluorescence-based molecular imaging of in vivo release kinetics$57,066
F32 · FY2017 · EB · contact PI